Tanabe Pharma America, Inc.

This study tested the long-term safety of an oral form of edaravone in 124 people with ALS over 96 weeks. Participants took the drug in cycles of 10 days on and 14 days off. The main goal was to see how safe and tolerable the treatment was over time.

This study looked at the long-term safety of an oral form of edaravone in 185 adults with ALS. Participants took the medication for 24 to 48 weeks, and researchers tracked any side effects. The goal was to see if taking the drug by mouth is safe over time for people with this pro…

This study tested a new drug called MT-7117 (dersimelagon) in 76 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. Participants received either the drug or a placebo for 52 weeks. The main goal …

This study tested a drug called MT-3921 (Unasnemab) in 72 people with recent severe neck spinal cord injuries. The goal was to see if it could improve arm and hand function better than a placebo. Participants received the drug or placebo by IV over 6 months, and their motor score…

This study tested a drug called MT-7117 in 165 adults and adolescents (ages 12-75) with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), conditions that cause severe pain from sunlight exposure. The goal was to see if the drug could delay the first symptoms o…

This study tested an experimental drug called MT-8554 to see if it could reduce the number and intensity of hot flashes in women going through menopause. About 375 women who had at least 7 moderate to severe hot flashes per day took either the drug or a placebo. The goal was to f…

This study looked at the long-term safety and effects of the drug MT-8554 in 190 postmenopausal women with moderate to severe hot flashes. All participants had completed a previous 12-week study of the same drug. Researchers monitored side effects, blood pressure, heart rate, and…

This study tested a drug called MT-7117 in 184 people aged 12 to 75 with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight. The goal was to see if the drug could delay the first signs of sun sensitivity (bur…

This phase 2 trial tested a drug called MT-7117 in 102 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight. Participants took either a low dose, high dose, or placebo daily for 16 weeks. The goal was to see if the drug could inc…

This study tested a drug called MT-2990 in 76 women with surgically diagnosed endometriosis and moderate to severe pelvic pain. Participants received either the drug or a placebo over 16 weeks. The goal was to see if MT-2990 safely reduces pain, including non-menstrual pelvic pai…

This study gave 6 healthy men a single oral dose of [14C]-MT-8554, a drug with a radioactive tag, to see how it is absorbed, broken down, and eliminated in urine and feces. Researchers measured drug levels in blood over time and checked for side effects. The goal was purely to un…

This study tested whether MT-8554, an experimental drug, changes the heart's electrical activity (QT interval) in 48 healthy adults aged 18 to 55. Participants received either a low dose, high dose, or a placebo. The goal was to measure safety, not to treat any disease. Results h…